search
Back to results

Sympathetic Mapping/ Ablation of Renal Nerves Trial (SMART) HTN-OFF MED Study (SMART OFF-MED)

Primary Purpose

Essential Hypertension, Vascular Diseases, Cardiovascular Diseases

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Renal nerve stimulation, mapping and denervation
Sham Procedure: Renal angiography
Sponsored by
The Second Affiliated Hospital of Chongqing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Essential Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and non-pregnant female subjects, 18≤age≤65
  2. Essential hypertension
  3. Office SBP ≥150mmHg and < 180mmHg; and DBP ≥90mmHg
  4. Average 24-hour ABPM systolic blood pressure is ≥130mmHg, or day-time mean SBP ≥135mmHg, or night-time mean SBP ≥120mmHg, and all SBP of ABMP record <170mmHg
  5. HPLC-MS/MS urinary antihypertensive drugs detection shows negative result after at least two weeks of drug elution period, or one extra week of drug elution period will be given for the second urinary drugs analysis; and the urinary drugs detection can be given in screening date for the subjects without antihypertensive history
  6. Renal arteries meet the criteria of renal nerve stimulation, mapping and denervation; and at least one positive-response point occurs in each renal artery
  7. Patient understands the purpose of this study, and is willing to participate and sign the Informed Consent
  8. Patient is compliant and willing to complete clinical follow-up.

Exclusion Criteria:

1. Renal artery anatomy is unqualified including:

  1. Diameter <3.5mm or treatable length <25mm;
  2. Multiple renal arteries and the main renal artery supplies a fraction of the blood flow less than 75%
  3. Renal artery stenosis >50% or any renal artery aneurysms on either side
  4. History of renal artery percutaneous transluminal angioplasty (PTA), including balloon angioplasty and stenting 2. eGFR <45ml/min/1.73m2 (MDRD formula) 3. Hospitalized within one year due to hypertensive crisis 4. Pulse pressure>80mmHg, or isolated systolic hypertension 5. During running in period, using any antihypertensive drugs without prescription and urinary drugs test shows positive.

6. Participated other clinical trials including both drug and medical device studies within 3 months enrollment 7. Female with pregnant or lactating, or having plans for pregnancy within 1 year 8. Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy) 9. Patients previously or currently suffering from following diseases:

  1. Essential pulmonary arterial hypertension
  2. Type I diabetes
  3. Severe cardiac valvular stenosis with contradictions to significantly reduce blood pressure
  4. History of myocardial infraction (MI), unstable angina, syncope or cerebrovascular accidents within half year.
  5. History of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyroidism
  6. Any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia)
  7. Plans to have surgery or cardiovascular interventions within following 6 months
  8. Alcohol abuse or unknown drug dependence history
  9. Neuroticisms such as depression or anxiety disorders
  10. Non-compliant patients unable to finish the research per physician's requests 10. There is no positive-response point in any renal artery, or any contradictions to conduct renal artery stimulation and ablation

Sites / Locations

  • 2ndChongqingMU

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

RDN Group

Sham Group

Arm Description

renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.

renal artery angiography group, without any renal nerve stimulation, mapping or denervation

Outcomes

Primary Outcome Measures

Change in office systolic blood pressure

Secondary Outcome Measures

Change in average 24-hour Ambulatory Blood Pressure Monitoring (ABPM) systolic blood pressure (SBP)
Change in average day-time ABPM SBP
Change in average night-time ABPM SBP
Change in office diastolic blood pressure (DBP)
Change in mean arterial blood pressure
Change in the blood catecholamines levels of pre-procedure and 3 months after the procedure
Rate of renal artery stenosis assessed by CT angiography
(stenosis > 70% )
Rate of severe renal dysfunction
eGFR<15ml/min/m2 or renal function replacement therapy needed
Rate of adverse events (AEs), SAEs, and severe cardio-cerebrovascular events
Rate of all-cause death

Full Information

First Posted
March 20, 2019
Last Updated
March 22, 2019
Sponsor
The Second Affiliated Hospital of Chongqing Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT03885843
Brief Title
Sympathetic Mapping/ Ablation of Renal Nerves Trial (SMART) HTN-OFF MED Study
Acronym
SMART OFF-MED
Official Title
A Prospective, Multicenter, Blind, Randomized and Controlled Trial of Selected Renal Denervation by Renal Nerve Mapping for the Treatment of Hypertension (HTN) in the Absence of Antihypertensive Medications (OFF MED)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2019 (Anticipated)
Primary Completion Date
January 1, 2020 (Anticipated)
Study Completion Date
April 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Second Affiliated Hospital of Chongqing Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate the efficacy and safety of selected renal sympathetic denervation using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator in patients with hypertension in the absence of antihypertensive medications, or till the negative result was given by urinary antihypertensive drugs detection of high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) after at least two weeks of drug elution period. Then Office systolic blood pressure (SBP) is still ≥ 150mmHg, < 180mmHg, diastolic blood pressure (DBP) ≥ 90mmHg, and 24-hour mean SBP of ambulatory blood pressure measurement (ABPM) is ≥130mmHg, or day-time mean SBP ≥135mmHg, or night-time mean SBP ≥120mmHg, and all SBP of ABMP record <170mmHg. After then the patient will be included when the results of bilateral renal angiography meet the requirements of renal nerve stimulation, mapping and denervation conditions.
Detailed Description
This is a prospective, multicenter, blind, randomized and controlled trial, in which patients are of essential hypertension, but in the absence of antihypertensive medications. The patients will be informed, consent and get into a screening process. After at least two weeks of drug elution period HPLC-MS/MS urinary antihypertensive drugs detection will be given till the negative result, or one extra week of drug elution period will be given for the second urinary drugs analysis. Then Office systolic blood pressure (SBP) is still ≥ 150mmHg, < 180mmHg, diastolic blood pressure (DBP) ≥ 90mmHg, and 24-hour mean SBP of ambulatory blood pressure measurement (ABPM) is ≥130mmHg, or day-time mean SBP ≥135mmHg, or night-time mean SBP ≥120mmHg, and all SBP of ABMP record <170mmHg. These patients will conduct renal angiography, and the meet inclusion criteria individuals will be allocated to either renal nerve stimulation, mapping and denervation group (RDN group) or renal artery angiography group (Sham group) by a randomizing system in a 1:1 ratio (80 patients, 40 pairs). Physicians who perform post-procedure patient management and physicians who perform renal denervation procedures are blinded to each other. Patients will be followed at the 2nd day, the 7th day after the procedure or at discharge from hospital, 1st month, 2nd month, 3rd month. Urine samples will be collected for drug tests to determine drug compliance of a patient. Data collecting/management/statistical analysis and laboratory tests will be performed by independent, qualified organizations. Independent Data Safety and Monitoring Board/Clinical Events Committee (DSMB/CEC) are formed and responsible for assessments of protocol deviations and natures of serious adverse events (SAEs).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Hypertension, Vascular Diseases, Cardiovascular Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RDN Group
Arm Type
Experimental
Arm Description
renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
Arm Title
Sham Group
Arm Type
Sham Comparator
Arm Description
renal artery angiography group, without any renal nerve stimulation, mapping or denervation
Intervention Type
Procedure
Intervention Name(s)
Renal nerve stimulation, mapping and denervation
Intervention Description
After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
Intervention Type
Procedure
Intervention Name(s)
Sham Procedure: Renal angiography
Intervention Description
After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
Primary Outcome Measure Information:
Title
Change in office systolic blood pressure
Time Frame
3 months after the treatment
Secondary Outcome Measure Information:
Title
Change in average 24-hour Ambulatory Blood Pressure Monitoring (ABPM) systolic blood pressure (SBP)
Time Frame
3 months
Title
Change in average day-time ABPM SBP
Time Frame
3 months
Title
Change in average night-time ABPM SBP
Time Frame
3 months
Title
Change in office diastolic blood pressure (DBP)
Time Frame
3 months
Title
Change in mean arterial blood pressure
Time Frame
3 months
Title
Change in the blood catecholamines levels of pre-procedure and 3 months after the procedure
Time Frame
3 months
Title
Rate of renal artery stenosis assessed by CT angiography
Description
(stenosis > 70% )
Time Frame
3 months
Title
Rate of severe renal dysfunction
Description
eGFR<15ml/min/m2 or renal function replacement therapy needed
Time Frame
3 months
Title
Rate of adverse events (AEs), SAEs, and severe cardio-cerebrovascular events
Time Frame
3 months
Title
Rate of all-cause death
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and non-pregnant female subjects, 18≤age≤65 Essential hypertension Office SBP ≥150mmHg and < 180mmHg; and DBP ≥90mmHg Average 24-hour ABPM systolic blood pressure is ≥130mmHg, or day-time mean SBP ≥135mmHg, or night-time mean SBP ≥120mmHg, and all SBP of ABMP record <170mmHg HPLC-MS/MS urinary antihypertensive drugs detection shows negative result after at least two weeks of drug elution period, or one extra week of drug elution period will be given for the second urinary drugs analysis; and the urinary drugs detection can be given in screening date for the subjects without antihypertensive history Renal arteries meet the criteria of renal nerve stimulation, mapping and denervation; and at least one positive-response point occurs in each renal artery Patient understands the purpose of this study, and is willing to participate and sign the Informed Consent Patient is compliant and willing to complete clinical follow-up. Exclusion Criteria: 1. Renal artery anatomy is unqualified including: Diameter <3.5mm or treatable length <25mm; Multiple renal arteries and the main renal artery supplies a fraction of the blood flow less than 75% Renal artery stenosis >50% or any renal artery aneurysms on either side History of renal artery percutaneous transluminal angioplasty (PTA), including balloon angioplasty and stenting 2. eGFR <45ml/min/1.73m2 (MDRD formula) 3. Hospitalized within one year due to hypertensive crisis 4. Pulse pressure>80mmHg, or isolated systolic hypertension 5. During running in period, using any antihypertensive drugs without prescription and urinary drugs test shows positive. 6. Participated other clinical trials including both drug and medical device studies within 3 months enrollment 7. Female with pregnant or lactating, or having plans for pregnancy within 1 year 8. Patient with sleep apnea who needs chronic oxygen-breathing or mechanical ventilation support (for example, tracheostomy) 9. Patients previously or currently suffering from following diseases: Essential pulmonary arterial hypertension Type I diabetes Severe cardiac valvular stenosis with contradictions to significantly reduce blood pressure History of myocardial infraction (MI), unstable angina, syncope or cerebrovascular accidents within half year. History of primary aldosteronism, pheochromocytoma, aorta stenosis, hyperthyroidism or hyperparathyroidism Any disease conditions interfering the measurement of blood pressure (for instance, severe peripheral artery diseases, abdominal artery aneurysm, hemorrhagic disorders such as thrombocytopenia, hemophilia and severe anemia) Plans to have surgery or cardiovascular interventions within following 6 months Alcohol abuse or unknown drug dependence history Neuroticisms such as depression or anxiety disorders Non-compliant patients unable to finish the research per physician's requests 10. There is no positive-response point in any renal artery, or any contradictions to conduct renal artery stimulation and ablation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yuehui Yin, MD
Phone
0086-13508335502
Email
yinyh63@163.com
Facility Information:
Facility Name
2ndChongqingMU
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400010
Country
China

12. IPD Sharing Statement

Learn more about this trial

Sympathetic Mapping/ Ablation of Renal Nerves Trial (SMART) HTN-OFF MED Study

We'll reach out to this number within 24 hrs